LSI Medience (formerly Mitsubishi Medience) has technology for iPS-derived cardiomyocytes for drug testing

The cells are expected to be used in personalized toxicity evaluation of drugs.

LSI Medience press release, July 2, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year. Accept or Deny